I agree completely with Dr Jenkins' impression that Kt/V is clinically illogical for reasons explained in the Commentary he cites. 1 In addition, Eloot et al. have recently found better urea removal when patients are treated for a longer time (t) despite comparable Kt/V. 2 Those data illustrate one more reason why K, t, and V should not be combined as a single ratio; we have one more fact indicating the clinical 'illogic of Kt/V' . I respectfully disagree with his reason, however, because Kt/V41.0 does not indicate complete urea removal. The fact is revealed by his claim that urea reduction ratio (URR) reflects solute removal better than Kt/V. Urea kinetic equations prove that URR and Kt/V are tightly linked as the following illustrates:
Therefore, URR and Kt/V can be calculated from each other and one cannot reasonably argue in the same breath that URR is appropriate but Kt/V is not.
is not appropriate for evaluating clinical outcome, 1 it does reflect that URR and Kt/V41.0 is perfectly logical.
The confusion probably evolved from misleading statements suggesting Kt/V reflects a 'fractional clearance' of urea. For example, we find, ''To normalize for differences in the size and habitus of patients, a dose of hemodialysis (prescribed or delivered) is best described as the fractional clearance of urea as a function of its distribution volume (Kt/V)'' . 3 
(Emphasis added)
Such unclear statements likely suggested to many that when, for example, Kt/V ¼ 48 l/40 l ¼ 1.2 the 'fractional clearance' would be 120%, so those 40 l should be completely 'cleared'. Unfortunately, the concept is incorrect as I hope I have shown. Our paper 1 was not intended to praise the Kt/V concept of dialysis adequacy but to provide some constructive criticism. Jenkins raises some theoretical issues that relate to the validity of the whole Kt/V concept in the hemodialysis setting, whereas our paper drew attention to potential problems with the concept of using V, an estimate of total body water, to normalize estimated urea clearance. We provided some support for the use of a normalizing factor, which better reflects metabolic activity.
There are a number of issues. First, whether any measure of urea removal is sufficient to judge dialysis http://www.kidney-international.org l e t t e r t o t h e e d i t o r adequacy; second, if a measure of urea removal were to be used, whether a simple urea reduction ratio is acceptable or whether a measure that incorporates a normalizing factor is necessary; and finally -whether the widespread use of V as this normalizing factor is valid. Jenkins' criticisms relate to the second point whereas our paper addressed the third.
Focusing solely on normalized urea clearance presents a flawed view of dialysis adequacy. There are many other facets. Middle molecule removal is important. Reanalysis of data from the HEMO study has demonstrated that retention of b 2 microglobulin was associated with increased mortality. 2 In addition to solute clearances, dialysis prescription encompasses other goals, including sodium and water, divalent ion and acid-base homeostasis. Dialysis hypotension is more likely to occur when dialysis session time is shortened, because of increased ultrafiltration rates, and failure to achieve adequate sodium removal with increased interdialytic weight gains.
Although we have criticized the appropriateness of the use of Kt/V in prescribing hemodialysis, we do believe that an assessment of the amount of dialysis delivered is vital, unless very long and/or very frequent dialysis sessions are employed. Normalized urea clearance, although not perfect, is a useful marker of adequacy, though we believe it could be used more astutely. Our paper proposes that the normalizing factor should reflect metabolic activity, as use of V may risk under-dialysis in women and small men. We suggest that this should be borne in mind while we continue to use Kt/V, and that the adequacy targets should be adjusted in these two groups. We would like to confirm these results and highlight the potential role of sterol regulatory element-binding proteins (SREBPs) in the above-mentioned disturbances. SREBPs are nuclear transcription factors that are currently regarded as the major regulators of both cholesterologenesis and lipogenesis.
We have shown that both gene expression and protein abundance of SREBPs are increased in white adipose tissue 2 and livers 3 of chronic kidney disease rats. Moreover, increase in SREBP expression has been demonstrated in kidneys of diabetic mice 4 and in experimental age-related nephropathy, 5 where it has been clearly linked to lipid deposition in glomeruli, and consequently to mesangial expansion, glomerulosclerosis, and proteinuria.
These results complement the findings demonstrated by Zhao et al. as they bring us closer to elucidating the issue of altered lipid metabolism in the course of chronic kidney disease. 3 
